Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients with Atrial Fibrillation

Stroke

Volumn 47, Issue 10, 2016, Pages 2462-2469

  Chao, Tze Fan ^a,f   Lip, Gregory Y H ^g   Liu, Chia Jen ^b,f   Tuan, Ta Chuan ^a,f   Chen, Su Jung ^c,f   Wang, Kang Ling ^a,f   Lin, Yenn Jiang ^a,f   Chang, Shih Lin ^a,f   Lo, Li Wei ^a,f   Hu, Yu Feng ^a,f   Chen, Tzeng Ji ^d   Chiang, Chern En ^a,e,f   Chen, Shih Ann ^a,f  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Department of Internal Medicine Division of Hematology   (Taiwan)

^c Division of Infectious Diseases   (Taiwan)

^d General Clinical Research Center ^*  (Taiwan)

^e General Clinical Research Center   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

age; atrial fibrillation; CHA2DS2 VASc score; ischemic stroke; modified CHA2DS2 VASc score

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

ADULT; AGED; ARTICLE; ASIAN; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHAD2DS2 VASC SCORE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MODIFIED CHA2DS2 VASC SCORE; NATIONAL HEALTH INSURANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; TAIWAN; TRANSIENT ISCHEMIC ATTACK; VALIDATION STUDY; VASCULAR DISEASE; AGE; COMPLICATION; MIDDLE AGED; STROKE;

AGE FACTORS; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; STROKE; TAIWAN; WARFARIN;

EID: 84987678206     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.116.013880     Document Type: Article

References (40)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fbrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fbrillation: an update of the 2010 ESC Guidelines for the management of atrial fbril-lation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747. doi: 10.1093/ eurheartj/ehs253.
3. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fbrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76. doi: 10.1016/j.jacc.2014.03.022.
4. Chao TF, Liu CJ, Tuan TC, Chen SJ, Wang KL, Lin YJ, et al. Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratifcation in atrial fbrillation: which scoring system should be used for Asians? Heart Rhythm. 2016;13:46-53. doi: 10.1016/j.hrthm.2015.08.017.
5. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboem-bolism in atrial fbrillation. Circ J. 2012;76:2289-2304.
6. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refning clinical risk stratifcation for predicting stroke and thromboembolism in atrial fbrillation using a novel risk factor-based approach: the Euro heart survey on atrial fbrillation. Chest. 2010;137:263-272. doi: 10.1378/ chest.09-1584.
7. Chao TF, Wang KL, Liu CJ, Lin YJ, Chang SL, Lo LW, et al. Age threshold for increased stroke risk among patients with atrial fbril-lation: a Nationwide Cohort Study From Taiwan. J Am Coll Cardiol. 2015;66:1339-1347. doi: 10.1016/j.jacc.2015.07.026.
8. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fbrilla-tion. Circ Cardiovasc Qual Outcomes. 2011;4:14-21. doi: 10.1161/ CIRCOUTCOMES.110.958108.
9. Chao TF, Huang YC, Liu CJ, Chen SJ, Wang KL, Lin YJ, et al. Acute myocardial infarction in patients with atrial fbrillation with a CHA2DS2-VASc score of 0 or 1: a nationwide cohort study. Heart Rhythm. 2014;11:1941-1947. doi: 10.1016/j.hrthm.2014.08.003.
10. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, et al. Using the CHA2DS2-VASc score for refning stroke risk stratifcation in 'low-risk' Asian patients with atrial fbrillation. J Am Coll Cardiol. 2014;64:1658-1665. doi: 10.1016/j.jacc.2014.06.1203.
11. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, et al. Should atrial fbrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015;65:635-642. doi: 10.1016/j.jacc.2014.11.046.
12. Chao TF, Liu CJ, Tuan TC, Chen SJ, Wang KL, Lin YJ, et al. Rate-control treatment and mortality in atrial fbrillation. Circulation. 2015;132:1604-1612. doi: 10.1161/CIRCULATIONAHA.114.013709.
13. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc. 2005;104:157-163.
14. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20:236-242. doi: 10.1002/ pds.2087.
15. Chao TF, Liu CJ, Chen SJ, Wang KL, Lin YJ, Chang SL, et al. Does digoxin increase the risk of ischemic stroke and mortality in atrial fbril-lation? A nationwide population-based cohort study. Can J Cardiol. 2014;30:1190-1195. doi: 10.1016/j.cjca.2014.05.009.
16. Lin LJ, Cheng MH, Lee CH, Wung DC, Cheng CL, Kao Yang YH. Compliance with antithrombotic prescribing guidelines for patients with atrial fbrillation-a nationwide descriptive study in Taiwan. Clin Ther. 2008;30:1726-1736. doi: 10.1016/j.clinthera.2008.09.010.
17. Chang CH, Lee YC, Tsai CT, Chang SN, Chung YH, Lin MS, et al. Continuation of statin therapy and a decreased risk of atrial fbrillation/fut-ter in patients with and without chronic kidney disease. Atherosclerosis. 2014;232:224-230. doi: 10.1016/j.atherosclerosis.2013.11.036.
18. Hsieh CY, Chen CH, Li CY, Lai ML. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Med Assoc. 2015;114:254-259. doi: 10.1016/j.jfma.2013.09.009.
19. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, et al. The net clinical beneft of warfarin anticoagulation in atrial fbrillation. Ann Intern Med. 2009;151:297-305.
20. Connolly SJ, Eikelboom JW, Ng J, Hirsh J, Yusuf S, Pogue J, et al; ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators. Net clinical beneft of adding clopidogrel to aspirin therapy in patients with atrial fbrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med. 2011;155:579-586. doi: 10.7326/0003-4819-155-9-201111010-00004.
21. Lip GY, Skjøth F, Nielsen PB, Larsen TB. Non-valvular atrial fbrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical beneft analysis for warfarin, aspirin, or no therapy. Thromb Haemost. 2015;114:826-834. doi: 10.1160/ TH15-07-0565.
22. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al. Anticoagulation control and prediction of adverse events in patients with atrial fbrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1:84-91. doi: 10.1161/CIRCOUTCOMES.108.796185.
23. Sjögren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, et al. Safety and effcacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost. 2015;113:1370-1377. doi: 10.1160/TH14-10-0859.
24. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;110:1087-1107. doi: 10.1160/TH13-06-0443.
25. Lip GY, Lane DA. Modern management of atrial fbrillation requires initial identifcation of "low-risk" patients using the CHA2DS2-VASc score, and not focusing on "high-risk" prediction. Circ J. 2014;78:1843-1845.
26. Siu CW, Lip GY, Lam KF, Tse HF. Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fbrillation in Hong Kong. Heart Rhythm. 2014;11:1401-1408. doi: 10.1016/j.hrthm.2014.04.021.
27. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fbrillation: an Asian perspective. Thromb Haemost. 2014;111:789-797. doi: 10.1160/ TH13-11-0948.
28. Hori M, Connolly SJ, Zhu J, Liu LS, Lau C P, Pais P, et al; RE-LY Investigators. Dabigatran versus warfarin: effects on ischemic and hemor-rhagic strokes and bleeding in Asians and non-Asians with atrial fbrillation. Stroke. 2013;44:1891-1896. doi: 10.1161/STROKEAHA.113.000990.
29. Wong KS, Hu DY, Oomman A, Tan RS, Patel MR, Singer DE, et al; Executive Steering Committee and the ROCKET AF Study Investigators. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke. 2014;45:1739-1747. doi: 10.1161/ STROKEAHA.113.002968.
30. Goto S, Zhu J, Liu L, Oh BH, Wojdyla DM, Aylward P, et al; ARISTOTLE Investigators. Effcacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fbrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J. 2014;168:303-309. doi: 10.1016/j.ahj.2014.06.005.
31. Xiong Q, Chen S, Senoo K, Proietti M, Hong K, Lip GY. The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fbrillation: a systemic review and meta-analysis. Int J Cardiol. 2015;195:237-242. doi: 10.1016/j. ijcard.2015.05.115.
32. Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation. 2011;124:314-323. doi: 10.1161/CIRCULATIONAHA.111.018820.
33. Wong LK. Global burden of intracranial atherosclerosis. Int J Stroke. 2006;1:158-159. doi: 10.1111/j.1747-4949.2006.00045.x.
34. Roldán V, Marín F, Manzano-Fernández S, Gallego P, Vílchez JA, Valdés M, et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fbrillation. J Am Coll Cardiol. 2013;62:2199-2204. doi: 10.1016/j.jacc.2013.08.1623.
35. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fbrillation. J Am Coll Cardiol. 2007;50:309-315. doi: 10.1016/j. jacc.2007.01.098.
36. Lip GY, Wang KL, Chiang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fbrillation: time for a reappraisal. Int J Cardiol. 2015;180:246-254. doi: 10.1016/j.ijcard.2014.11.182.
37. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fbrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 2000;35:183-187.
38. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S, et al; ACTIVE W Investigators. Incidence of stroke in paroxysmal versus sustained atrial fbrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol. 2007;50:2156-2161. doi: 10.1016/j.jacc.2007.07.076.
39. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, et al. Risk of ischaemic stroke according to pattern of atrial fbrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J. 2015;36:281-287a. doi: 10.1093/eurheartj/ehu307.
40. Friberg L, Rosenqvist M, Lip GY. Net clinical beneft of warfarin in patients with atrial fbrillation: a report from the Swedish atrial fbril-lation cohort study. Circulation. 2012;125:2298-2307. doi: 10.1161/ CIRCULATIONAHA.111.055079.